Cialis Dares to Be Different

 

Cialis is the drug with the ear-catching TV commercial. A man and a woman repose on their outdoor sun deck -- sitting in his-and-her bathtubs -- contemplating the countryside as an announcer intones about the drug's 36-hour window of opportunity and warns about the (rare) side effects of four-hour erections.

When you're the newest entrant in a pharmaceutical market, you need to capture the public's attention quickly.

The people promoting Cialis -- the biotechnology company Icos and the multinational drug giant Eli Lilly (LLY) -- tried something that their competitors hadn't tried before. They ran a TV ad that described what an impotence drug does.

But in order to present such an ad, they also had to list Cialis' possible side-effects. That's a requirement by the Food and Drug Administration, which says, in effect, that ads describing what a drug does for you must also say what the drug can do to you.

This type of ad is common in newspapers and magazines, where readers can check the fine print about side effects, but the descriptive format is becoming more common on television for anything from cholesterol fighters to antidepressants to antihistamines.

But Cialis, which reached the U.S. market in late November, was the first impotence drug to use such a TV commercial. The ad made its debut during the Super Bowl.

A Strategic Decision

"The first launch advantage is a very powerful advantage in pharmaceutical marketing," said Leonard Blum, vice president of sales and marketing for Icos of Bothell, Wash., referring to the five-year-plus head start for Viagra and the three-month lead for Levitra.

Because drug marketing depends on what the FDA allows on a drug's label, Eli Lilly and Icos decided to promote the drug's major distinction: It stays in the body longer than the competitors' drugs. Even the FDA remarks that Cialis is "different" than other medications because it can improve erectile function for up to 36 hours.

TheStreet Premium Services    For Personal Service: 877-471-2967

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
New: ETF Profits
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Doug Kass
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,890.46 1,351.95 2,927.23 20.47
Oil *
118.75
UP
6.51
UP
1.99
UP
11.37
UP
0.72
10 Yr
2.05%
SPDR Gold
168.02
+0.05%
+0.15%
+0.39%
+3.65%
Data delayed 20 minutes

Top Stories and Tools

Brokerage Partners

After the Bell

Before the Bell

Booyah! Newsletter

ETF Daily

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet